QuikReader

QuikReader

  • Latest
  • Top stories
  • Business
  • Tech
  • World
  • Politics
  • Sports
  • Lifestyle
  • Health
  • Science
  • Entertainment
  • More
    • Sources
Sign in

Latest in Abbvie’s

Sort by
4 items

  • AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

    AbbVie’s “pain” is Bristol Myers Squibb’s “gain,” says Truist Securities analyst Srikripa Devarakonda.
    Business - MarketWatch - 2 days ago

  • Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

    Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
    Business - MarketWatch - 3 days ago
  • AbbVie shares tumble after schizophrenia drug disappoints

    AbbVie shares tumble after schizophrenia drug disappoints

    US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms
    Business - Financial Times - 3 days ago

  • AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease

    Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
    Business - MarketWatch - October 17
  • 1
  Follow topic
© 2024 QuikReader - About - Terms - Privacy